Literature DB >> 14688017

Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents.

Emanuela Barletta1, Giuseppe Gorini, Paolo Vineis, Lucia Miligi, Laura Davico, Gabriele Mugnai, Stefania Ciolli, Franco Leoni, Marilena Bertini, Giuseppe Matullo, Adele Seniori Costantini.   

Abstract

Mutations of the N- and K-ras genes occur in approximately 15-30% of acute myeloid leukaemia patients. The role of the oncogenic ras in leukaemogenesis remains unclear. Few studies have revealed that mutations in the ras oncogene family are more probably found in acute myeloid leukaemia patients with previous exposure to toxic agents. A case-case study was conducted in the areas of Florence and Turin, Italy, to investigate whether the presence of N- and K-ras mutations in acute myeloid leukaemia patients was related to a higher frequency of exposure to chemicals. During a 3-year period, 111 acute myeloid leukaemia patients were enrolled. All the patients were interviewed using a semi-structured questionnaire collecting data on residential history, occupation, personal habits and pathological history. The presence of N- and K-ras mutations was analysed by amplification and synthetic oligonucleotide probes and by the so-called polymerase chain reaction amplification for specific alleles technique. A total of 34 (30.6%) patients were found to harbour ras mutations in N-ras and/or K-ras. Fourteen patients (12.6%) had a single ras mutation and 20 patients (18%) had two ras mutations. A positive association between a priori at risk jobs and ras mutations was found, based on nine exposed cases; the odds ratio, adjusted by age, sex and previous X-ray and/or chemotherapy was 2.8 (95% confidence intervals: 0.9-9.0). When considering only subjects with two ras mutations the odds ratio was 4.8 (95% confidence intervals: 1.2-18.8). The odds ratio for a previous X-ray and/or chemotherapy was 16.2 (95% confidence intervals: 1.8-755.9); when only subjects with two ras mutations were considered, the odds ratio was 26.1 (95% confidence intervals: 2.5-1248.9). In conclusion, our data suggest that ras oncogene mutations might identify a group of leukaemia in people with previous X-ray/chemotherapy or with exposure to chemical agents in the work environment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688017     DOI: 10.1093/carcin/bgh057

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

1.  Tobacco Smoke and Ras Mutations Among Latino and Non-Latino Children with Acute Lymphoblastic Leukemia.

Authors:  Maneet Kaur; Adam J de Smith; Steve Selvin; Luoping Zhang; Marc Cunningham; Michelle W Kang; Helen M Hansen; Robert M Cooper; Roberta McKean-Cowdin; Joseph L Wiemels; Catherine Metayer
Journal:  Arch Med Res       Date:  2016-11       Impact factor: 2.235

2.  Loss of heterozygosity of Kras2 gene on 12p12-13 in Chinese colon carcinoma patients.

Authors:  Jun Wan; Hong Li; Yuan Li; Mei-Ling Zhu; Po Zhao
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

3.  The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations.

Authors:  Chan Kwon Jung; Mark P Little; Jay H Lubin; Alina V Brenner; Samuel A Wells; Alice J Sigurdson; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2013-11-18       Impact factor: 5.958

4.  Intact expression status of RASSF1A in acute myeloid leukemia.

Authors:  Davood Zare-Abdollahi; Shamsi Safari; Abolfazl Movafagh; Mojtaba Ghadiani; Sahand Riazi-Isfahani; Mir Davood Omrani
Journal:  Med Oncol       Date:  2013-11-19       Impact factor: 3.064

Review 5.  The Prenatal Origin of Childhood Leukemia: Potential Applications for Epidemiology and Newborn Screening.

Authors:  Erin L Marcotte; Logan G Spector; Daniela P Mendes-de-Almeida; Heather H Nelson
Journal:  Front Pediatr       Date:  2021-04-23       Impact factor: 3.418

6.  The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine.

Authors:  Ebtesam I Ahmad; Heba H Gawish; Nashwa Ma Al Azizi; Ashraf M Elhefni
Journal:  Onco Targets Ther       Date:  2011-07-15       Impact factor: 4.147

7.  Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.

Authors:  Zeba N Singh; Yogesh Jethava; Ginell R Post; Daisy Alapat; Jeffrey Sawyer; Sarah Waheed; Bijay Nair; Saad Z Usmani; Clyde Bailey; Nathan Petty; Frits Van Rhee; Bart Barlogie
Journal:  Clin Case Rep       Date:  2015-02-13

Review 8.  Acute myeloid leukaemia at an early age: Reviewing the interaction between pesticide exposure and KMT2A-rearrangement.

Authors:  Maria S Pombo-de-Oliveira; Francianne Gomes Andrade; Gisele Dallapicola Brisson; Filipe Vicente Dos Santos Bueno; Ingrid Sardou Cezar; Elda Pereira Noronha
Journal:  Ecancermedicalscience       Date:  2017-11-30

9.  RAS mutations in early age leukaemia modulated by NQO1 rs1800566 (C609T) are associated with second-hand smoking exposures.

Authors:  Francianne Gomes Andrade; Juliana Montibeller Furtado-Silva; Bruno Alves de Aguiar Gonçalves; Luiz Claudio Santos Thuler; Thayana Conceição Barbosa; Mariana Emerenciano; André Siqueira; Maria S Pombo-de-Oliveira
Journal:  BMC Cancer       Date:  2014-02-26       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.